Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results. The study met its primary endpoint, with tilrekimig showing a ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. For atopic dermatitis, there are many ...
51.9% for the middle tested dose; and 49.4% for the high tested dose. The two highest dose levels tested with tilrekimig strongly suggest potentially meaningful improvements to approved standard of ...
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
DUBLIN--(BUSINESS WIRE)--The "Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The clinical trial report ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic ...
Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo Tilrekimig ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results